AXSM clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system, it is accelerating the completion of the ADVANCE-1 Phase 2/3 trial of AXS-05 in patients with Alzheimer’s disease agitation to ensure the safety of this vulnerable patient population during the COVID-19 pandemic. i expect that this end of the month its increasing thoroughly. Are you guys ready to get through resistance? why not?
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在
使用條款閱讀更多資訊。